Ocular safety profile and intraocular pharmacokinetics of an antagonist of EphB4/EphrinB2 signalling

British Journal of Ophthalmology

Volumn 94, Issue 12, 2010, Pages 1668-1673

  Brar, Manpreet ^a   Cheng, Lingyun ^a   Yuson, Ritchie ^a   Mojana, Francesca ^a   Freeman, William R ^a   Gill, Parkash S ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b Vasgene Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPHRIN RECEPTOR B4; SOLUBLE MONOMERIC EPHRIN RECEPTOR B4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOROID; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SAFETY; DRUG TISSUE LEVEL; ELECTRORETINOGRAM; HISTOPATHOLOGY; INTRAOCULAR PRESSURE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RETINA; SUBRETINAL NEOVASCULARIZATION; VITREOUS BODY;

ANIMALS; CHOROID; ELECTRORETINOGRAPHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPHRIN-B2; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; RABBITS; RECEPTOR, EPHB4; RETINA; VITREOUS BODY;

EID: 78649869202     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2010.182881     Document Type: Article

References (30)

1. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 2004;122:598-614.
2. Wells JA, Murthy R, Chibber R, et al. Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. Br J Ophthalmol 1996;80:363-6.
3. Lopez PF, Sippy BD, Lambert HM, et al. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1996;37:855-68.
4. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
5. Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006;26:859-70.
6. Adams RH, Klein R. Eph receptors and ephrin ligands. Essential mediators of vascular development. Trends Cardiovasc Med 2000;10:183-8.
7. He S, Ding Y, Zhou J, et al. Soluble EphB4 regulates choroidal endothelial cell function and inhibits laser-induced choroidal neovascularization. Invest Ophthalmol Vis Sci 2005;46:4772-9.
8. Davies MH, Zamora DO, Smith JR, et al. Soluble ephrin-B2 mediates apoptosis in retinal neovascularization and in endothelial cells. Microvasc Res 2009;77:382-6.
9. Ehlken C, Martin G, Lange C, et al. Therapeutic interference with EphrinB2 signalling inhibits oxygen-induced angioproliferative retinopathy. Acta Ophthalmol. Published Online First: 2009 Sep 17. doi:10.1111/j.1755-3768.2009. 01609.x.
10. Zamora DO, Davies MH, Planck SR, et al. Soluble forms of EphrinB2 and EphB4 reduce retinal neovascularization in a model of proliferative retinopathy. Invest Ophthalmol Vis Sci 2005;46:2175-82.
11. Nussenblatt RB, Palestine AG, Chan CC, et al. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 1985;92:467-71.
12. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509-16.
13. Cheng L, Hostetler KY, Chaidhawangul S, et al. Treatment or prevention of herpes simplex virus retinitis with intravitreally injectable crystalline 1-O-hexadecylpropanediol-3-phospho-ganciclovir. Invest Ophthalmol Vis Sci 2002;43:515-21.
14. Cheng L, Hostetler KY, Gardner MF, et al. Intravitreal toxicology in rabbits of two preparations of 1-O-octadecyl-sn-glycerol-3-phosphonoformate, a sustained-delivery anti-CMV drug. Invest Ophthalmol Vis Sci 1999;40:1487-95.
15. Cheng L, Hostetler KY, Lee J, et al. Characterization of a novel intraocular drug-delivery system using crystalline lipid antiviral prodrugs of ganciclovir and cyclic cidofovir. Invest Ophthalmol Vis Sci 2004;45:4138-44.
16. Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26:495-511.
17. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 2007;114:2179-82.
18. Mordenti J, Cuthbertson RA, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 1999;27:536-44.
19. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855-9.
20. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16.
21. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008;246:81-7.
22. Davson H, Luck CP. A comparative study of the total carbon dioxide in the ocular fluids, cerebrospinal fluid, and plasma of some mammalian species. J Physiol 1956;132:454-64.
23. Zhou G, Williams RW. Mouse models for the analysis of myopia: an analysis of variation in eye size of adult mice. Optom Vis Sci 1999;76:408-18.
24. Avci B, Avci R, Inan UU, et al. Comparative evaluation of apoptotic activity in photoreceptor cells after intravitreal injection of bevacizumab and pegaptanib sodium in rabbits. Invest Ophthalmol Vis Sci 2009;50:3438-46.
25. Chen J, Hicks D, Brantley-Sieders D, et al. Inhibition of retinal neovascularization by soluble EphA2 receptor. Exp Eye Res 2006;82:664-73.
26. Gaudreault J, Fei D, Rusit J, et al. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005;46:726-33.
27. Yu DY, Cringle SJ. Oxygen distribution in the mouse retina. Invest Ophthalmol Vis Sci 2006;47:1109-12.
28. Yu DY, Cringle SJ, Alder VA, et al. Intraretinal oxygen distribution in rats as a function of systemic blood pressure. Am J Physiol Heart Circ Physiol 1994;267:H2498-507.
29. Sha O, Kwong WH. Postnatal developmental changes of vitreous and lens volumes in Sprague-Dawley rats. Neuroembryology Aging 2006;4:183-8.
30. Berkowitz B, Lukaszew R, Mullins C, et al. Impaired hyaloidal circulation function and uncoordinated ocular growth patterns in experimental retinopathy of prematurity. Invest Ophthalmol Vis Sci 1998;39:391-6.